Changzhi Medical College, No. 161, Jiefangdong Street, Changzhi, 046000, Shanxi Province, China.
Department of Orthopaedics, Heping Hospital Affiliated to Changzhi Medical College, Yanannan Road, Changzhi, 046000, Shanxi, China.
BMC Musculoskelet Disord. 2020 May 28;21(1):330. doi: 10.1186/s12891-020-03334-x.
Several studies have been performed to investigate association between IL-6 174G/C (rs1800795) and 572C/G (rs1800796) gene polymorphisms and osteoporosis predisposition. However, the results were conflicting. So, we performed a meta-analysis designed to provide more reliable results for the association between IL-6 gene polymorphisms and osteoporosis.
Studies were searched using PubMed, EMBASE, the Cochrane Library and Wanfang electronic databases. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between IL-6 174G/C (rs1800795) and 572C/G (rs1800796) gene polymorphisms and osteoporosis risk. The false-positive report probabilities (FPRP) test and the venice criteria were used to assess the credibility of statistically significant associations.
A total of 9 studies with 1891 osteoporosis patients and 2027 healthy controls were included in current meta-analysis. Overall, The IL-6 174G/C (rs1800795) gene polymorphism was insignificantly associated with osteoporosis vulnerability. For IL-6 572C/G (rs1800796), statistically significant elevated osteoporosis vulnerability was found in IL-6 572C/G additive model (OR = 2.25, 95% CI: 1.55-3.26), dominant model (OR = 1.42, 95% CI: 0.78-2.56) and recessive model (OR = 1.96, 95% CI: 1.36-2.83). However, the IL-6 572C/G C allele was found to be associated with reduced susceptibility to osteoporosis (OR = 0.76, 95% CI: 0.56-1.04). When excluding studies that did not conform to HWE, the results did not change significantly. Further, when we evaluated the credibility of the positive results of the current meta-analysis, we identified less credible positive results in IL-6 572C/G recessive and additive model.
In conclusion, IL-6 572C/G GG genotype may be associated with increased risk of osteoporosis.
已有多项研究旨在探讨白细胞介素 6(IL-6)基因 174G/C(rs1800795)和 572C/G(rs1800796)基因多态性与骨质疏松易感性之间的关联。然而,研究结果存在差异。因此,我们进行了一项荟萃分析,旨在为 IL-6 基因多态性与骨质疏松症之间的关联提供更可靠的结果。
使用 PubMed、EMBASE、Cochrane 图书馆和万方电子数据库检索研究。计算比值比(OR)和 95%置信区间(CI)来评估 IL-6 174G/C(rs1800795)和 572C/G(rs1800796)基因多态性与骨质疏松症风险之间的关联。采用虚假阳性报告概率(FPRP)检验和威尼斯标准评估统计学显著关联的可信度。
共有 9 项研究纳入了 1891 例骨质疏松症患者和 2027 例健康对照者,总计纳入 1891 例骨质疏松症患者和 2027 例健康对照者。总体而言,IL-6 174G/C(rs1800795)基因多态性与骨质疏松症易感性无显著相关性。对于 IL-6 572C/G(rs1800796),在 IL-6 572C/G 加性模型(OR=2.25,95%CI:1.55-3.26)、显性模型(OR=1.42,95%CI:0.78-2.56)和隐性模型(OR=1.96,95%CI:1.36-2.83)中发现统计学上显著增加的骨质疏松症易感性。然而,IL-6 572C/G C 等位基因与骨质疏松症的易感性降低相关(OR=0.76,95%CI:0.56-1.04)。当排除不符合 HWE 的研究时,结果没有显著变化。此外,当我们评估当前荟萃分析阳性结果的可信度时,我们发现 IL-6 572C/G 隐性和加性模型中可信度较低的阳性结果。
综上所述,IL-6 572C/G GG 基因型可能与骨质疏松症风险增加相关。